NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oragenics Inc. Presentation at Sequire Investor Summit 2026
TL;DR
Oragenics presents at Sequire Investor Summit 2026, highlighting ONP-002's potential as a first-in-class treatment for concussion, offering investors early access to a novel neurological therapy.
Oragenics uses intranasal delivery technology to advance ONP-002 through Phase 2a clinical trials in Australia, with U.S. Phase IIb trials planned for concussion treatment.
Oragenics' ONP-002 addresses the significant unmet medical need in concussion and mild traumatic brain injury, potentially improving neurological care for patients worldwide.
Oragenics will present at the Sequire Investor Summit in Puerto Rico, showcasing its intranasal platform that could treat conditions from Parkinson's to PTSD.
Found this article helpful?
Share it with your network and spread the knowledge!
Oragenics Inc. (NYSE American: OGEN) announced it will present at the upcoming Sequire Investor Summit 2026, where it plans to highlight its novel approach to treating concussion and mild traumatic brain injury and progress with its ONP-002 clinical program.
The summit is scheduled for January 20-22, 2026, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.
Oragenics Inc. is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, with a focus on addressing significant unmet medical needs in neurological care.
ONP-002 is Oragenics' lead candidate being advanced as a potential first-in-class treatment for concussion and mild traumatic brain injury, an area where no approved drug therapies currently exist.
Oragenics is progressing ONP-002 through Phase 2a clinical trials in Australia, with U.S. Phase IIb trials planned to follow.
It addresses a significant unmet medical need in concussion and mild traumatic brain injury, where no approved drug therapies currently exist, according to CEO Janet Huffman.
The platform has potential applications across multiple neurological conditions including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
While not explicitly stated who will present, the content mentions that Oragenics Chief Executive Officer Janet Huffman provided the information about the company's plans for the summit.
The latest news and updates relating to OGEN are available in the company's newsroom at https://ibn.fm/OGEN, and the full press release can be viewed at https://ibn.fm/Gn84M.
BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences sectors, and it published this announcement as part of its distribution services within the InvestorBrandNetwork portfolio.
Curated from InvestorBrandNetwork (IBN)
